Cell & Gene: The Podcast
During this first episode of Cell & Gene: The Podcast, Host Erin Harris talks to Enzyvant’s CEO Rachelle Jacques about the biotech’s lead asset, investigational regenerative therapy RVT-802 for congenital athymia. Jacques provides an update on FDA approval and details what’s next for RVT-802. She explains tissue-based therapies — how far they’ve come and the work that’s left to be done. And, they discuss what being patient-focused means in the world of rare diseases.
THE VOICES OF A BURGEONING MARKET
Cell & Gene, the most valuable resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, brings you Cell & Gene: The Podcast. Join us as Cell & Gene Chief Editor, Erin Harris interviews industry and academic leaders on what they’re working on and how it's moving the sector forward. Each episode of Cell & Gene: The Podcast will explore approved and pipeline therapies, new trends in manufacturing, the long, regulated road to commercialization, and everything in between.